1
|
Shintani Y, Kato K, Kawami M, Takano M, Kumamoto T. Direct N 1-Selective Alkylation of Hydantoins Using Potassium Bases. Chem Pharm Bull (Tokyo) 2021; 69:407-410. [PMID: 33790085 DOI: 10.1248/cpb.c20-00857] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Hydantoins, including the antiepileptic drug phenytoin, contain an amide nitrogen and an imide nitrogen, both of which can be alkylated. However, due to the higher acidity of its proton, N3 can be more easily alkylated than N1 under basic conditions. In this study, we explored methods for direct N1-selective methylation of phenytoin and found that conditions using potassium bases [potassium tert-butoxide (tBuOK) and potassium hexamethyldisilazide (KHMDS)] in tetrahydrofuran (THF) gave N1-monomethylated phenytoin in good yield. The applicable scope of this reaction system was found to include various hydantoins and alkyl halides. To explore the function of methylated hydantoins, the effects of a series of methylated phenytoins on P-glycoprotein were examined, but none of methylated products showed inhibitory activity toward rhodamine 123 efflux by P-glycoprotein.
Collapse
Affiliation(s)
- Yumi Shintani
- Department of Synthetic Organic Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University
| | - Koichi Kato
- Integrative Brain Imaging Center, National Center of Neurology and Psychiatry
| | - Masashi Kawami
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University
| | - Mikihisa Takano
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University
| | - Takuya Kumamoto
- Department of Synthetic Organic Chemistry, Graduate School of Biomedical and Health Sciences, Hiroshima University
| |
Collapse
|
2
|
Eriksson J, Antoni G, Långström B, Itsenko O. The development of 11C-carbonylation chemistry: A systematic view. Nucl Med Biol 2021; 92:115-137. [PMID: 32147168 DOI: 10.1016/j.nucmedbio.2020.02.005] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2020] [Accepted: 02/16/2020] [Indexed: 12/18/2022]
Abstract
The prospects for using carbon-11 labelled compounds in molecular imaging has improved with the development of diverse synthesis methods, including 11C-carbonylations and refined techniques to handle [11C]carbon monoxide at a nanomole scale. Facilitating biological research and molecular imaging was the driving force when [11C]carbon monoxide was used in the first in vivo application with carbon-11 in human (1945) and when [11C]carbon monoxide was used for the first time as a chemical reagent in the synthesis of [11C]phosgene (1978). This review examines a rich plethora of labelled compounds synthesized from [11C]carbon monoxide, their chemistry and use in molecular imaging. While the strong development of the 11C-carbonylation chemistry has expanded the carbon-11 domain considerably, it could be argued that the number of 11C-carbonyl compounds entering biological investigations should be higher. The reason for this may partly be the lack of commercially available synthesis instruments designed for 11C-carbonylations. But as this review shows, novel and greatly simplified methods to handle [11C]carbon monoxide have been developed. The next important challenge is to make full use of these technologies and synthesis methods in PET research. When there is a PET-tracer that meets a more general need, the incentive to implement 11C-carbonylation protocols will increase.
Collapse
Affiliation(s)
- Jonas Eriksson
- Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden.
| | - Gunnar Antoni
- Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden
| | - Bengt Långström
- Department of Chemistry, Uppsala University, Uppsala, Sweden
| | - Oleksiy Itsenko
- Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden
| |
Collapse
|
3
|
Liger F, Cadarossanesaib F, Iecker T, Tourvieille C, Le Bars D, Billard T. 11
C-Labeling: Intracyclic Incorporation of Carbon-11 into Heterocycles. European J Org Chem 2019. [DOI: 10.1002/ejoc.201901386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | | | | | | | - Didier Le Bars
- CERMEP-In vivo imaging; 59 Bd Pinel 69677 Lyon France
- Institute of Chemistry and Biochemistry (UMR CNRS 5246); Univ Lyon, Université Lyon 1; 43 Bd du 11 novembre 1918 69622 Villeurbanne France
| | - Thierry Billard
- CERMEP-In vivo imaging; 59 Bd Pinel 69677 Lyon France
- Institute of Chemistry and Biochemistry (UMR CNRS 5246); Univ Lyon, Université Lyon 1; 43 Bd du 11 novembre 1918 69622 Villeurbanne France
| |
Collapse
|
4
|
Taddei C, Pike VW. [ 11C]Carbon monoxide: advances in production and application to PET radiotracer development over the past 15 years. EJNMMI Radiopharm Chem 2019; 4:25. [PMID: 31659516 PMCID: PMC6751244 DOI: 10.1186/s41181-019-0073-4] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Accepted: 07/22/2019] [Indexed: 12/18/2022] Open
Abstract
[11C]Carbon monoxide is an appealing synthon for introducing carbon-11 at a carbonyl position (C=O) in a wide variety of chemotypes (e.g., amides, ketones, acids, esters, and ureas). The prevalence of the carbonyl group in drug molecules and the present-day broad versatility of carbonylation reactions have led to an upsurge in the production of this synthon and in its application to PET radiotracer development. This review focuses on the major advances of the past 15 years.
Collapse
Affiliation(s)
- Carlotta Taddei
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Rm B3C342, Bethesda, MD, 20892-1003, USA.
| | - Victor W Pike
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Rm B3C342, Bethesda, MD, 20892-1003, USA
| |
Collapse
|
5
|
Schembri LS, Eriksson J, Odell LR. Palladium(0)-Catalyzed Carbonylative Synthesis of N-Acylsulfonamides via Regioselective Acylation. J Org Chem 2019; 84:6970-6981. [DOI: 10.1021/acs.joc.9b00740] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Luke S. Schembri
- Department of Medicinal Chemistry, Uppsala Biomedical Center, Uppsala University, P. O. Box 574, Uppsala SE-751 23, Sweden
| | - Jonas Eriksson
- Department of Medicinal Chemistry, Uppsala Biomedical Center, Uppsala University, P. O. Box 574, Uppsala SE-751 23, Sweden
| | - Luke R. Odell
- Department of Medicinal Chemistry, Uppsala Biomedical Center, Uppsala University, P. O. Box 574, Uppsala SE-751 23, Sweden
| |
Collapse
|
6
|
van der Wildt B, Shen B, Chin FT. Efficient synthesis of carbon-11 labelled acylsulfonamides using [ 11C]CO carbonylation chemistry. Chem Commun (Camb) 2019; 55:3124-3127. [PMID: 30793132 DOI: 10.1039/c8cc09661a] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Herein, a novel method for carbon-11 labeling of acyl sulfonamides by a one-step insertive [11C]CO carbonylative cross-coupling reaction between aryl halides and sulfonamides is presented. Various model compounds as well as drug molecules LY573636 (tasisulam) and ABT-199 were obtained in excellent yields. This method provides a valuable and widely applicable contribution to the continuously expanding radiochemical toolbox for PET research.
Collapse
Affiliation(s)
- Berend van der Wildt
- Stanford University, School of Medicine, Department of Radiology, Molecular Imaging Program at Stanford (MIPS), 1201 Welch Road, PS049, Stanford, CA 4305-5484, USA.
| | | | | |
Collapse
|
7
|
Deng X, Rong J, Wang L, Vasdev N, Zhang L, Josephson L, Liang SH. Chemistry for Positron Emission Tomography: Recent Advances in 11 C-, 18 F-, 13 N-, and 15 O-Labeling Reactions. Angew Chem Int Ed Engl 2019; 58:2580-2605. [PMID: 30054961 PMCID: PMC6405341 DOI: 10.1002/anie.201805501] [Citation(s) in RCA: 195] [Impact Index Per Article: 39.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2018] [Indexed: 01/07/2023]
Abstract
Positron emission tomography (PET) is a molecular imaging technology that provides quantitative information about function and metabolism in biological processes in vivo for disease diagnosis and therapy assessment. The broad application and rapid advances of PET has led to an increased demand for new radiochemical methods to synthesize highly specific molecules bearing positron-emitting radionuclides. This Review provides an overview of commonly used labeling reactions through examples of clinically relevant PET tracers and highlights the most recent developments and breakthroughs over the past decade, with a focus on 11 C, 18 F, 13 N, and 15 O.
Collapse
Affiliation(s)
- Xiaoyun Deng
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Jian Rong
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Lu Wang
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Neil Vasdev
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Lei Zhang
- Medicine Design, Pfizer Inc., Cambridge, MA, 02139, USA
| | - Lee Josephson
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| | - Steven H Liang
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA, 02114, USA
| |
Collapse
|
8
|
Deng X, Rong J, Wang L, Vasdev N, Zhang L, Josephson L, Liang SH. Chemie der Positronenemissionstomographie: Aktuelle Fortschritte bei
11
C‐,
18
F‐,
13
N‐ und
15
O‐Markierungsreaktionen. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201805501] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Xiaoyun Deng
- Division of Nuclear Medicine and Molecular ImagingMassachusetts General Hospital & Department of RadiologyHarvard Medical School Boston MA 02114 USA
| | - Jian Rong
- Division of Nuclear Medicine and Molecular ImagingMassachusetts General Hospital & Department of RadiologyHarvard Medical School Boston MA 02114 USA
| | - Lu Wang
- Division of Nuclear Medicine and Molecular ImagingMassachusetts General Hospital & Department of RadiologyHarvard Medical School Boston MA 02114 USA
| | - Neil Vasdev
- Division of Nuclear Medicine and Molecular ImagingMassachusetts General Hospital & Department of RadiologyHarvard Medical School Boston MA 02114 USA
| | - Lei Zhang
- Medicine DesignPfizer Inc. Cambridge MA 02139 USA
| | - Lee Josephson
- Division of Nuclear Medicine and Molecular ImagingMassachusetts General Hospital & Department of RadiologyHarvard Medical School Boston MA 02114 USA
| | - Steven H. Liang
- Division of Nuclear Medicine and Molecular ImagingMassachusetts General Hospital & Department of RadiologyHarvard Medical School Boston MA 02114 USA
| |
Collapse
|
9
|
Van der Wildt B, Shen B, Chin FT. A [ 11 C] CO dispensing system for rapid screening of carbonylation reactions. J Labelled Comp Radiopharm 2018; 61:1110-1114. [PMID: 30286517 DOI: 10.1002/jlcr.3686] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2018] [Accepted: 09/28/2018] [Indexed: 12/17/2022]
Abstract
[11 C] CO is a highly versatile synthon that allows for labeling at carbonyl positions of many molecules by means of transition metal-mediated carbonylation reactions. The intrinsic complexity of carbonylation reactions often requires tedious screening of reaction conditions for obtaining satisfying yields. Herein, a [11 C] CO dispending system for performing multiple reactions with a single batch of cyclotron-produced [11 C]CO2 is described. This semiautomated setup allows for more rapid and efficient screening of reactions and reaction conditions compared with the traditional "one beam for one reaction" strategy.
Collapse
Affiliation(s)
- Berend Van der Wildt
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, School of Medicine, Stanford, California, USA
| | - Bin Shen
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, School of Medicine, Stanford, California, USA
| | - Frederick T Chin
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, School of Medicine, Stanford, California, USA
| |
Collapse
|
10
|
Verbeek J, Eriksson J, Syvänen S, Huisman M, Schuit RC, Molthoff CFM, Voskuyl RA, de Lange EC, Lammertsma AA, Windhorst AD. Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([ 18F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression. EJNMMI Radiopharm Chem 2018; 3:11. [PMID: 30294663 PMCID: PMC6150866 DOI: 10.1186/s41181-018-0046-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Accepted: 07/18/2018] [Indexed: 01/16/2023] Open
Abstract
Background Several P-glycoprotein (P-gp) substrate tracers are available to assess P-gp function in vivo, but attempts to develop a tracer for measuring expression levels of P-gp have not been successful. Recently, (Z)-2-(5-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazine-carbothioamide was described as a potential selective P-gp inhibitor that is not transported by P-gp. Therefore, the purpose of this study was to radiolabel two of its analogues and to assess their potential for imaging P-gp expression using PET. Results [18F]2-(4-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazine-carbothioamide ([18F]5) and [18F]2-(6-fluoro-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazine-carbothioamide ([18F]6) were synthesized and both their biodistribution and metabolism were evaluated in rats. In addition, PET scans were acquired in rats before and after tariquidar (P-gp inhibitor) administration as well as in P-gp knockout (KO) mice. Both [18F]5 and [18F]6 were synthesized in 2–3% overall yield, and showed high brain uptake in ex vivo biodistribution studies. [18F]6 appeared to be metabolically unstable in vivo, while [18F]5 showed moderate stability with limited uptake of radiolabelled metabolites in the brain. PET studies showed that transport of [18F]5 across the blood-brain barrier was not altered by pre-treatment with the P-gp inhibitor tariquidar, and uptake was significantly lower in P-gp KO than in wild-type animals and indeed transported across the BBB or bound to P-gp in endothelial cells. Conclusion In conclusion, [18F]5 and [18F]6 were successfully and reproducibly synthesized, albeit with low radiochemical yields. [18F]5 appears to be a radiotracer that binds to P-gp, as showed in P-gp knock-out animals, but is not a substrate for P-gp.
Collapse
Affiliation(s)
- Joost Verbeek
- 1Department of Radiology & Nuclear Medicine, VU University Medical Center, P.O. box 7057, 1007 MB Amsterdam, The Netherlands
| | - Jonas Eriksson
- 1Department of Radiology & Nuclear Medicine, VU University Medical Center, P.O. box 7057, 1007 MB Amsterdam, The Netherlands.,3Present Address: Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
| | - Stina Syvänen
- 2Division of Pharmacology, LACDR, Leiden University, Leiden, The Netherlands.,3Present Address: Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
| | - Marc Huisman
- 1Department of Radiology & Nuclear Medicine, VU University Medical Center, P.O. box 7057, 1007 MB Amsterdam, The Netherlands
| | - Robert C Schuit
- 1Department of Radiology & Nuclear Medicine, VU University Medical Center, P.O. box 7057, 1007 MB Amsterdam, The Netherlands
| | - Carla F M Molthoff
- 1Department of Radiology & Nuclear Medicine, VU University Medical Center, P.O. box 7057, 1007 MB Amsterdam, The Netherlands
| | - Rob A Voskuyl
- 2Division of Pharmacology, LACDR, Leiden University, Leiden, The Netherlands.,4Stichting Epilepsie Instellingen Nederland, SEIN, Heemstede, The Netherlands
| | | | - Adriaan A Lammertsma
- 1Department of Radiology & Nuclear Medicine, VU University Medical Center, P.O. box 7057, 1007 MB Amsterdam, The Netherlands
| | - Albert D Windhorst
- 1Department of Radiology & Nuclear Medicine, VU University Medical Center, P.O. box 7057, 1007 MB Amsterdam, The Netherlands
| |
Collapse
|
11
|
Dahl K, Ulin J, Schou M, Halldin C. Reduction of [11C]CO2to [11C]CO using solid supported zinc. J Labelled Comp Radiopharm 2017; 60:624-628. [DOI: 10.1002/jlcr.3561] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Revised: 08/28/2017] [Accepted: 08/30/2017] [Indexed: 12/19/2022]
Affiliation(s)
- Kenneth Dahl
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatric Research; Karolinska Hospital; Stockholm Sweden
| | - Johan Ulin
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatric Research; Karolinska Hospital; Stockholm Sweden
| | - Magnus Schou
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatric Research; Karolinska Hospital; Stockholm Sweden
- AstraZeneca PET Science Centre, Department of Clinical Neuroscience; Karolinska Institutet; Stockholm Sweden
| | - Christer Halldin
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatric Research; Karolinska Hospital; Stockholm Sweden
| |
Collapse
|
12
|
Tang F, Hartz AMS, Bauer B. Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers. Front Neurol 2017; 8:301. [PMID: 28729850 PMCID: PMC5498483 DOI: 10.3389/fneur.2017.00301] [Citation(s) in RCA: 269] [Impact Index Per Article: 38.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Accepted: 06/12/2017] [Indexed: 01/16/2023] Open
Abstract
Epilepsy is a common neurological disorder that affects over 70 million people worldwide. Despite the recent introduction of new antiseizure drugs (ASDs), about one-third of patients with epilepsy have seizures refractory to pharmacotherapy. Early identification of patients who will become refractory to ASDs could help direct such patients to appropriate non-pharmacological treatment, but the complexity in the temporal patterns of epilepsy could make such identification difficult. The target hypothesis and transporter hypothesis are the most cited theories trying to explain refractory epilepsy, but neither theory alone fully explains the neurobiological basis of pharmacoresistance. This review summarizes evidence for and against several major theories, including the pharmacokinetic hypothesis, neural network hypothesis, intrinsic severity hypothesis, gene variant hypothesis, target hypothesis, and transporter hypothesis. The discussion is mainly focused on the transporter hypothesis, where clinical and experimental data are discussed on multidrug transporter overexpression, substrate profiles of ASDs, mechanism of transporter upregulation, polymorphisms of transporters, and the use of transporter inhibitors. Finally, future perspectives are presented for the improvement of current hypotheses and the development of treatment strategies as guided by the current understanding of refractory epilepsy.
Collapse
Affiliation(s)
- Fei Tang
- Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, MN, United States.,Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, United States
| | - Anika M S Hartz
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, United States.,Department of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, KY, United States
| | - Björn Bauer
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, United States.,Epilepsy Center, University of Kentucky, Lexington, KY, United States
| |
Collapse
|
13
|
van Waarde A, Dierckx RAJO, Zhou X, Khanapur S, Tsukada H, Ishiwata K, Luurtsema G, de Vries EFJ, Elsinga PH. Potential Therapeutic Applications of Adenosine A 2A Receptor Ligands and Opportunities for A 2A Receptor Imaging. Med Res Rev 2017; 38:5-56. [PMID: 28128443 DOI: 10.1002/med.21432] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 10/31/2016] [Accepted: 11/14/2016] [Indexed: 12/13/2022]
Abstract
Adenosine A2A receptors (A2A Rs) are highly expressed in the human striatum, and at lower densities in the cerebral cortex, the hippocampus, and cells of the immune system. Antagonists of these receptors are potentially useful for the treatment of motor fluctuations, epilepsy, postischemic brain damage, or cognitive impairment, and for the control of an immune checkpoint during immunotherapy of cancer. A2A R agonists may suppress transplant rejection and graft-versus-host disease; be used to treat inflammatory disorders such as asthma, inflammatory bowel disease, and rheumatoid arthritis; be locally applied to promote wound healing and be employed in a strategy for transient opening of the blood-brain barrier (BBB) so that therapeutic drugs and monoclonal antibodies can enter the brain. Increasing A2A R signaling in adipose tissue is also a potential strategy to combat obesity. Several radioligands for positron emission tomography (PET) imaging of A2A Rs have been developed in recent years. This review article presents a critical overview of the potential therapeutic applications of A2A R ligands, the use of A2A R imaging in drug development, and opportunities and limitations of PET imaging in future research.
Collapse
Affiliation(s)
- Aren van Waarde
- University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, 1, 9713 GZ, Groningen, The Netherlands
| | - Rudi A J O Dierckx
- University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, 1, 9713 GZ, Groningen, The Netherlands.,Department of Nuclear Medicine, University Hospital, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium
| | - Xiaoyun Zhou
- University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, 1, 9713 GZ, Groningen, The Netherlands
| | - Shivashankar Khanapur
- University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, 1, 9713 GZ, Groningen, The Netherlands
| | - Hideo Tsukada
- Central Research Laboratory, Hamamatsu Photonics K.K., Hamakita, Hamamatsu, Shizuoka 434-8601, Japan
| | - Kiichi Ishiwata
- Research Institute of Cyclotron and Drug Discovery Research, Southern TOHOKU Research Institute for Neuroscience, 7-115 Yatsuyamada, Koriyama, 963-8052, Japan.,Department of Biofunctional Imaging, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.,Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 173-0015, Japan
| | - Gert Luurtsema
- University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, 1, 9713 GZ, Groningen, The Netherlands
| | - Erik F J de Vries
- University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, 1, 9713 GZ, Groningen, The Netherlands
| | - Philip H Elsinga
- University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, 1, 9713 GZ, Groningen, The Netherlands
| |
Collapse
|
14
|
Chow SY, Odell LR, Eriksson J. Low-Pressure Radical11C-Aminocarbonylation of Alkyl Iodides through Thermal Initiation. European J Org Chem 2016. [DOI: 10.1002/ejoc.201601106] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Shiao Y. Chow
- Department of Medicinal Chemistry; Division of Organic Pharmaceutical Chemistry; Uppsala University; 75123 Uppsala Sweden
| | - Luke R. Odell
- Department of Medicinal Chemistry; Division of Organic Pharmaceutical Chemistry; Uppsala University; 75123 Uppsala Sweden
| | - Jonas Eriksson
- Department of Medicinal Chemistry; Division of Organic Pharmaceutical Chemistry; Uppsala University; 75123 Uppsala Sweden
| |
Collapse
|
15
|
Mansor S, Yaqub M, Boellaard R, Froklage FE, de Vries A, Bakker ED, Voskuyl RA, Eriksson J, Schwarte LA, Verbeek J, Windhorst AD, Lammertsma AA. Parametric Methods for Dynamic 11C-Phenytoin PET Studies. J Nucl Med 2016; 58:479-483. [DOI: 10.2967/jnumed.116.178707] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 08/29/2016] [Indexed: 01/13/2023] Open
|
16
|
Rotstein BH, Liang SH, Placzek MS, Hooker JM, Gee AD, Dollé F, Wilson AA, Vasdev N. (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals. Chem Soc Rev 2016; 45:4708-26. [PMID: 27276357 PMCID: PMC5000859 DOI: 10.1039/c6cs00310a] [Citation(s) in RCA: 80] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The positron-emitting radionuclide carbon-11 ((11)C, t1/2 = 20.3 min) possesses the unique potential for radiolabeling of any biological, naturally occurring, or synthetic organic molecule for in vivo positron emission tomography (PET) imaging. Carbon-11 is most often incorporated into small molecules by methylation of alcohol, thiol, amine or carboxylic acid precursors using [(11)C]methyl iodide or [(11)C]methyl triflate (generated from [(11)C]carbon dioxide or [(11)C]methane). Consequently, small molecules that lack an easily substituted (11)C-methyl group are often considered to have non-obvious strategies for radiolabeling and require a more customized approach. [(11)C]Carbon dioxide itself, [(11)C]carbon monoxide, [(11)C]cyanide, and [(11)C]phosgene represent alternative reactants to enable (11)C-carbonylation. Methodologies developed for preparation of (11)C-carbonyl groups have had a tremendous impact on the development of novel PET tracers and provided key tools for clinical research. (11)C-Carbonyl radiopharmaceuticals based on labeled carboxylic acids, amides, carbamates and ureas now account for a substantial number of important imaging agents that have seen translation to higher species and clinical research of previously inaccessible targets, which is a testament to the creativity, utility and practicality of the underlying radiochemistry.
Collapse
Affiliation(s)
| | - Steven H Liang
- Massachusetts General Hospital, Harvard Medical School, Boston, USA.
| | - Michael S Placzek
- Athinoula A. Martinos Center for Biomedical Imaging, MGH, HMS, Charlestown, USA and McLean Hospital, Belmont, USA
| | - Jacob M Hooker
- Athinoula A. Martinos Center for Biomedical Imaging, MGH, HMS, Charlestown, USA
| | | | - Frédéric Dollé
- CEA - Institut d'imagerie biomédicale, Service hospitalier Frédéric Joliot, Université Paris-Saclay, Orsay, France
| | - Alan A Wilson
- Centre for Addiction and Mental Health, Toronto, Canada
| | - Neil Vasdev
- Massachusetts General Hospital, Harvard Medical School, Boston, USA.
| |
Collapse
|
17
|
Toyohara J, Okamoto M, Aramaki H, Zaitsu Y, Shimizu I, Ishiwata K. ( R )-[ 11 C]Emopamil as a novel tracer for imaging enhanced P-glycoprotein function. Nucl Med Biol 2016; 43:52-62. [DOI: 10.1016/j.nucmedbio.2015.09.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2015] [Revised: 08/31/2015] [Accepted: 09/03/2015] [Indexed: 11/28/2022]
|
18
|
Abstract
Epilepsy is a serious neurological disorder that affects more than 60 million people worldwide. Intractable epilepsy (IE) refers to approximately 20%-30% of epileptic patients who fail to achieve seizure control with antiepileptic drug (AED) treatment. Although the mechanisms underlying IE are not well understood, it has been hypothesized that multidrug transporters such as P-glycoprotein (P-gp) play a major role in drug efflux at the blood-brain barrier, and may be the underlying factor in the variable responses of patients to AEDs. The main goal of the present review is to show evidence from different areas that support the idea that the overexpression of P-gp is associated with IE. We discuss here evidence from animal studies, pharmacology, clinical cases and genetic studies.
Collapse
Affiliation(s)
- Guang-Xin Wang
- a Medical Institute of Paediatrics , Qilu Children's Hospital of Shandong University , Jinan , P.R. China
| | - Da-Wei Wang
- b Department of Biochemistry and Molecular Biology , School of Medicine, Shandong University , Jinan , P.R. China
| | - Yong Liu
- a Medical Institute of Paediatrics , Qilu Children's Hospital of Shandong University , Jinan , P.R. China
| | - Yan-Hui Ma
- a Medical Institute of Paediatrics , Qilu Children's Hospital of Shandong University , Jinan , P.R. China
| |
Collapse
|
19
|
Mansor S, Boellaard R, Froklage FE, Bakker ED, Yaqub M, Voskuyl RA, Schwarte LA, Verbeek J, Windhorst AD, Lammertsma A. Quantification of Dynamic 11C-Phenytoin PET Studies. J Nucl Med 2015; 56:1372-7. [DOI: 10.2967/jnumed.115.158055] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2015] [Accepted: 06/23/2015] [Indexed: 01/27/2023] Open
|
20
|
Bankstahl JP. What does a picture tell? In vivo imaging of ABC transporter function. DRUG DISCOVERY TODAY. TECHNOLOGIES 2014; 12:e113-9. [PMID: 25027369 DOI: 10.1016/j.ddtec.2014.03.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Activity of ABC transporters in tumor tissue or at the blood–brain barrier is believed to be responsible for treatment failure of substrate drugs. As this mechanism will not be present in every single patient, diagnostic tools to study transporter function are urgently needed. Many efforts were made over the past years to improve in vivo quantification of ABC transporter function by molecular imaging techniques. This includes development of new positron emitting tracers, but also the evaluation of modified experimental protocols using already existing tracers. In addition to imaging of transporter function in healthy animals or volunteers, results from disease models or human patients are covered in this review.
Collapse
|
21
|
Poot AJ, van der Wildt B, Stigter-van Walsum M, Rongen M, Schuit RC, Hendrikse NH, Eriksson J, van Dongen GAMS, Windhorst AD. [¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer. Nucl Med Biol 2013; 40:488-97. [PMID: 23522977 DOI: 10.1016/j.nucmedbio.2013.02.002] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2012] [Revised: 01/07/2013] [Accepted: 02/02/2013] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Tyrosine kinase inhibitors (TKIs) like sorafenib are important anticancer therapeutics with thus far limited treatment response rates in cancer patients. Positron emission tomography (PET) could provide the means for selection of patients who might benefit from TKI treatment, if suitable PET tracers would be available. The aim of this study was to radiolabel sorafenib (1) with carbon-11 and to evaluate its potential as TKI-PET tracer in vivo. METHODS Synthetic methods were developed in which sorafenib was labeled at two different positions, followed by a metabolite analysis in rats and a PET imaging study in tumor-bearing mice. RESULTS [methyl-(11)C]-1 and [urea-(11)C]-1 were synthesized in yields of 59% and 53%, respectively, with a purity of >99%. The identity of the products was confirmed by coinjection on HPLC with reference sorafenib. In an in vivo metabolite analysis [(11)C]sorafenib proved to be stable. The percentage of intact product in blood-plasma after 45 min was 90% for [methyl-(11)C]-1 and 96% for [urea-(11)C]-1, respectively. Due to the more reliable synthesis, further research regarding PET imaging was performed with [methyl-(11)C]-1 in nude mice bearing FaDu (head and neck cancer), MDA-MB-231 (breast cancer) or RXF393 (renal cancer) xenografts. Highest tracer accumulation at a level of 2.52 ± 0.33%ID/g was observed in RXF393, a xenograft line extensively expressing the sorafenib target antigen Raf-1 as assessed by immunohistochemistry. CONCLUSION In conclusion, we have synthesized [(11)C]sorafenib as PET tracer, which is stable in vivo and has the capability to be used as PET tracer for imaging in tumor-bearing mice.
Collapse
Affiliation(s)
- Alex J Poot
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Syvänen S, Eriksson J. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem Neurosci 2013; 4:225-37. [PMID: 23421673 DOI: 10.1021/cn3001729] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Efflux transporter P-glycoprotein (P-gp) at the blood-brain barrier (BBB) restricts substrate compounds from entering the brain and may thus contribute to pharmacoresistance observed in patient groups with refractory epilepsy and HIV. Altered P-gp function has also been implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Positron emission tomography (PET), a molecular imaging modality, has become a promising method to study the role of P-gp at the BBB. The first PET study of P-gp function was conducted in 1998, and during the past 15 years two main categories of P-gp PET tracers have been investigated: tracers that are substrates of P-gp efflux and tracers that are inhibitors of P-gp function. PET, as a noninvasive imaging technique, allows translational research. Examples of this are preclinical investigations of P-gp function before and after administering P-gp modulating drugs, investigations in various animal and disease models, and clinical investigations regarding disease and aging. The objective of the present review is to give an overview of available PET radiotracers for studies of P-gp and to discuss how such studies can be designed. Further, the review summarizes results from PET studies of P-gp function in different central nervous system disorders.
Collapse
Affiliation(s)
- Stina Syvänen
- Department of Public Health and Caring Sciences, Uppsala University, Rudbecklaboratoriet, 751 85 Uppsala, Sweden
| | - Jonas Eriksson
- PET Centre, Uppsala University Hospital, 751 85 Uppsala, Sweden
- Preclinical PET Platform, Department
of Medicinal Chemistry, Uppsala University, Dag Hammarskjöldsv 14C, 751 83 Uppsala, Sweden
| |
Collapse
|